Sign Up to like & get
recommendations!
3
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-2702
Abstract: Background: GQ1001 was developed to overcome the current limitation of existing HER2 ADCs by using the next generation site-specific conjugation and a stable linker technology, coined the intelligent ligase-dependent conjugation (iLDC) technology. iLDC provides a…
read more here.
Keywords:
gq1001;
her2;
her2 targeting;
generation ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct178
Abstract: Background: GQ1001 is a novel HER2-targeted antibody-drug conjugate (ADC) that was developed using innovative conjugation technologies coined intelligent Ligase-Dependent Conjugation (iLDC), that can significantly improves homogeneity and biostability of ADC. In preclinical studies, GQ1001 showed…
read more here.
Keywords:
dose;
gq1001;
her2;
phase study ... See more keywords